James Chih-Hsin Yang
Overview
Explore the profile of James Chih-Hsin Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
250
Citations
15991
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Janne P, Planchard D, Kobayashi K, Cheng Y, Lee C, Valdiviezo N, et al.
Future Oncol
. 2025 Mar;
:1-12.
PMID: 40051276
No abstract available.
2.
Planchard D, Janne P, Cheng Y, Yang J, Yanagitani N, Kim S, et al.
Future Oncol
. 2025 Feb;
:1-13.
PMID: 39995095
No abstract available.
3.
Huang Y, Hsu C, Huang D, Yang J, Wu S
J Formos Med Assoc
. 2025 Jan;
PMID: 39880703
Background: Inflammatory myofibroblastic tumors (IMTs), rare soft tissue neoplasms, are characterized by a blend of myofibroblastic proliferation and inflammatory features. While generally characterized by slow growth, IMTs can exhibit locally...
4.
Lee C, Liao B, Subramaniam S, Chiu C, Mersiades A, Ho C, et al.
JTO Clin Res Rep
. 2025 Jan;
6(2):100771.
PMID: 39877028
Introduction: -mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed...
5.
Wang H, Liao W, Ho C, Wu S, Yang C, Hsu C, et al.
Eur J Cancer
. 2025 Jan;
217:115224.
PMID: 39799785
Background: Inadequate tumour samples often hinder molecular testing in non-small cell lung cancer (NSCLC). Plasma-based cell-free DNA (cfDNA) sequencing has shown promise in bypassing these tissue limitations. Nevertheless, pleural effusion...
6.
Spira A, Cho B, Felip E, Garon E, Goto K, Johnson M, et al.
Lung Cancer
. 2025 Jan;
199:108066.
PMID: 39764938
No abstract available.
7.
Besse B, Goto K, Wang Y, Lee S, Marmarelis M, Ohe Y, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39755170
Introduction: Treatment options for patients with EGFR-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited. Methods: CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients...
8.
Wu S, Ho C, Yang J, Yu S, Lin Y, Lin S, et al.
Clin Transl Med
. 2024 Dec;
15(1):e70149.
PMID: 39715697
Background: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) remains a significant hurdle for patients with EGFR-mutated non-small cell lung cancer (NSCLC), particularly those lacking the...
9.
Yang C, Liao W, Ho C, Chen K, Tsai T, Hsu C, et al.
J Formos Med Assoc
. 2024 Dec;
PMID: 39694766
Background: PD-L1 is associated with poor efficacy of first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in untreated EGFR-mutant non-small-cell lung cancer (NSCLC). Whether PD-L1 is...
10.
Wang M, Xu Y, Huang W, Su W, Gao B, Lee C, et al.
Lung Cancer
. 2024 Dec;
199:108053.
PMID: 39647463
Background: Multiple agents can be used to treat patients with EGFR mutated non-small cell lung cancer (NSCLC) who develop resistance to EGFR tyrosine kinase inhibitors (TKIs), but the clinical outcome...